CN113209201A - 一种治疗各种癌症的中药组合物 - Google Patents
一种治疗各种癌症的中药组合物 Download PDFInfo
- Publication number
- CN113209201A CN113209201A CN202110715494.1A CN202110715494A CN113209201A CN 113209201 A CN113209201 A CN 113209201A CN 202110715494 A CN202110715494 A CN 202110715494A CN 113209201 A CN113209201 A CN 113209201A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- root
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims description 13
- 201000011510 cancer Diseases 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 27
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 8
- 241000296615 Celastrus strigillosus Species 0.000 claims abstract description 7
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract description 7
- 241000203383 Schefflera Species 0.000 claims abstract description 7
- 235000017309 Hypericum perforatum Nutrition 0.000 claims abstract description 6
- 244000141009 Hypericum perforatum Species 0.000 claims abstract description 6
- 240000000377 Tussilago farfara Species 0.000 claims abstract description 6
- 235000004869 Tussilago farfara Nutrition 0.000 claims abstract description 6
- 235000007756 Akebia quinata Nutrition 0.000 claims abstract description 5
- 240000008027 Akebia quinata Species 0.000 claims abstract description 5
- 235000008694 Humulus lupulus Nutrition 0.000 claims abstract description 5
- 241001571764 Lysimachia christinae Species 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 210000000582 semen Anatomy 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 240000007371 Cuscuta campestris Species 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 20
- 238000011282 treatment Methods 0.000 abstract description 9
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000036737 immune function Effects 0.000 abstract description 3
- 231100000405 induce cancer Toxicity 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 21
- 210000004881 tumor cell Anatomy 0.000 description 15
- 230000001737 promoting effect Effects 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 229940044683 chemotherapy drug Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000036457 multidrug resistance Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 description 3
- QOVWXXKVLJOKNW-UHFFFAOYSA-N hyperforin Natural products CC(C)C(=O)C12CC(CC=C(C)C)(CC(CC=C(C)C)C1CCC=C(C)C)C(=C(CC=C(C)C)C2=O)O QOVWXXKVLJOKNW-UHFFFAOYSA-N 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000019633 pungent taste Nutrition 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 241000208983 Arnica Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241001065361 Gynostemma Species 0.000 description 1
- RMFGNMMNUZWCRZ-UHFFFAOYSA-N Humulone Natural products CC(C)CC(=O)C1=C(O)C(O)(CC=C(C)C)C(O)=C(CC=C(C)C)C1=O RMFGNMMNUZWCRZ-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 241000632869 Pachira glabra Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000006214 castanha do maranho Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- VMSLCPKYRPDHLN-NRFANRHFSA-N humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)[C@@](O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-NRFANRHFSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗癌症的中药,是由下列重量份的原料药组成:皂角刺、啤酒花、漏芦5~10重量份;竹黄、款冬花、菟丝子6~12重量份;南蛇藤、贯叶金丝桃9~18重量份;七叶莲、绞股蓝、排钱树15~30重量份。本发明可以增强机体免疫功能,诱导癌细胞分化和凋亡、防止癌细胞转移,减轻患者痛苦、提高病人生存质量,具有治疗效果显著、无毒副作用等特点。
Description
技术领域
本发明涉及中药的制备领域,特别是涉及一种治疗癌症的中药组合物。
背景技术
在医学上,癌是指起源于上皮组织的恶性肿瘤,是恶性肿瘤中最常见的一类。相对应的,起源于间叶组织的恶性肿瘤统称为肉瘤。有少数恶性肿瘤不按上述原则命名,如肾母细胞瘤、恶性畸胎瘤等。一般人们所说的“癌症”习惯上泛指所有恶性肿瘤。
传统治疗方法有种种缺陷,手术治疗能将肿瘤切除,但是,手术风险高,手术对人体创伤大,使患者免疫力降低,对疾病抵抗力下降,手术为局部治疗手段,只适用于早期且身体状况能够耐受的患者;手术切除不能除根,会直接导致癌细胞扩散。
化疗药物几乎都是细胞毒性药物,在杀死肿瘤细胞的同时,对人体的正常细胞有一定的毒副作用,尤其是对分裂、增殖、比较快的细胞如骨髓造血细胞、胃肠道粘膜上皮细胞等。化疗会缩短患者生存时间且部分肿瘤对药物不敏感,化疗不可能彻底杀死体内所有癌细胞,在一定的时间内癌细胞还会复发或转移。
放射治疗常作为一种辅助治疗或姑息治疗手段。放射治疗在破坏肿瘤的同时,正常组织细胞也会受到一定的损害,超过这一限制剂量就会对组织产生不可逆损害,而且,放射治疗还可能降低机体的免疫力。放射的剂量是经过理论计算来完成,难以与实际相符合,只有小于 2cm 的肿瘤才能一次性完全破坏。
发明内容
本发明的目的在于改进已有技术的不足而提供一种治疗癌症的中药组合物,使其可以有效的抵抗癌细胞、防止癌细胞转移,提高了癌症患者的治愈率,具有治疗效果显著、无毒副作用等特点。
本发明提供了一种治疗癌症的中药组合物,该中药组合物包括:皂角刺、啤酒花、漏芦5~10重量份;竹黄、款冬花、菟丝子6~12重量份;南蛇藤、贯叶金丝桃9~18重量份;七叶莲、绞股蓝、排钱树15~30重量份。
在一个优选的实施方案中,所述治疗癌症的中药组合物由下列重量份的原料药组成:皂角刺、啤酒花、漏芦10重量份;竹黄、款冬花、菟丝子12重量份;南蛇藤、贯叶金丝桃18重量份;七叶莲、绞股蓝、排钱树30重量份。本发明还提供一种治疗癌症的口服制剂,该口服制剂由上述中药组合物制成。
其中,七叶莲:味辛;微苦;性温。祛风止痛;活血消肿。七叶莲具有很强的杀灭肿瘤细胞及抑制肿瘤生长作用。所含β-榄香烯是抗肿瘤有效成分。
贯叶金丝桃:味苦;涩;性平;归肝经。收敛止血;调经通乳;清热解毒;利湿。贯叶金丝桃素的 “抗癌谱 ”非常广 ,对多种癌症均有良好的疗效。贯叶金丝桃素能直接杀灭、引发凋亡和局部血管闭塞导致的续发性细胞死亡。贯叶金丝桃素具有显著的抗肿瘤活性、体内低毒性、天然资源含量丰富。贯叶金丝桃中含有相当丰富的黄酮类化合物,不仅对多种致癌剂、促癌剂有拮抗作用 ,而且可以抑制多类恶性肿瘤细胞的生长和转移。
漏芦:味苦,寒。归胃经。清热解毒,消痈,下乳,舒筋通脉。漏芦显著提高免疫功能,漏芦提取物对肿瘤具有抑制血管生成和诱导细胞凋亡作用,与化疗药合用,具有协同作用,可发挥明显增效、增敏、减毒作用,并可保护癌症患者的重要脏器和免疫器官,延长生存时间;体外实验显示,漏芦具有细胞毒作用,主要具有逆转耐药、诱导细胞凋亡作用,其作用靶点有:①显著下调多药耐药细胞耐药 基因P170蛋白的表达,抑制耐药细胞的膜转运活性,减少耐药细胞对化疗药物的外排,提高细胞内化疗药物浓度,逆转肿瘤细胞的多药耐药性;②抑制癌基因Bcl.2的表达,诱导肿瘤细胞凋亡,发挥逆转肿瘤细胞多药耐药作用;③显著降低肿瘤细胞端粒酶活性表达,抑制肿瘤细胞恶性增殖,防止其多药耐药的产生。
皂角刺:辛,温。归肝、胃经。消肿托毒。皂角刺中所含槲皮素具有较强的抗肿瘤活性,可诱导多种肿瘤细胞凋亡,对肿瘤有化学预防和治疗双重作用。槲皮素可抑制ras基因依赖型肿瘤细胞的增殖和迁移。皂角刺在抑制肿瘤血管生成和侵袭转移上可能有重要作用。
排钱树:淡、涩,平。有小毒。清热利湿,活血祛瘀,软坚散结。排钱树可以使肿瘤细胞变性坏死和纤维化。效果与秋水仙碱相近。
绞股蓝:味苦;微甘;性凉。归肺;脾;肾经。清热;补虚;解毒。绞股蓝不仅能提高细胞免疫功能,也增强体液免疫。可明显抑制瘤细胞DNA合成,对肿瘤细胞也有直接杀灭作用,而对正常细胞的增殖则无不良影响。绞股蓝既有防止正常细胞癌变,又有促使癌细胞逐渐恢复正常的功效。
南蛇藤:味苦、辛,性微温,归肝、脾、大肠经。祛风活血,消肿止痛。南蛇藤总萜对非小细胞肺癌、乳腺癌、结肠癌、鼻咽癌、神经胶质瘤、前列腺癌有显著细胞毒性。
款冬花:味辛;微甘;性温。归肺经。润肺下气;化痰止咳。款冬二醇和山金车二醇对促进肿瘤的多肽抗原活化EB病毒早期抗原有抑制作用。山金车二醇对各种人癌细胞系有广泛的细胞毒活性,浓度6mol/L可以抑制50%癌细胞生长。
啤酒花:苦;性微凉。归肝;胃经。健胃消食;利尿消肿;抗痨消炎。啤酒花所含葎草酮显著抑制内皮细胞增殖,具有显著抗肿瘤作用,是抑制肿瘤各种血管形成疾病、恶性肿瘤生长和转移的有效药物。
竹黄:味淡;辛;平。归肺;肝经。化痰止咳;活血祛风;利湿。竹黄对癌细胞亲和力大于正常组织,具有诱导细胞凋亡及抑制鮮瘤细胞増殖、杀伤癌细胞的作用。
菟丝子:甘,温。归肝、肾、脾经。滋补肝肾,固精缩尿,安胎,明目,止泻。菟丝子能明显抑制癌细胞DNA的合成,明显抑制恶性肿瘤的生长和扩散。
本发明是由中国传统的中草药制成,根据中医辨证论治及现代医学的若干原则,以某些成分确定、功效明晰的天然提取物的有序配伍,组合成了有诱导癌细胞凋亡与促使其分化的中药。
本发明既有化学治疗之功,又平和无毒,可谓“零毒化疗”。 用药多年来,患者无任何不良反应,跟踪血液检查正常,且疗效不反弹。5年生存率大幅提高。
本发明有“扶正培本、活血化瘀、散结止痛、提高患者免疫力作用”,可以使各中药成分在发挥其抗癌作用的同时相互协同,相辅相成,可以起到相互促进的作用,既能抑制癌细胞的增值,又能诱导癌细胞凋亡,起到治疗癌症的作用。本发明与手术治疗相结合可以促进患者康复,预防术后肿瘤的复发和转移,快速帮助患者康复。
本发明能够帮助晚期癌症患者改善症状、减轻痛苦、提高病人生存质量。对于已复发或转移及无法进行西医手术、放化疗治疗的患者,通过单独服用本配方中药,增强机体免疫功能,诱导癌细胞分化和凋亡,也可以达到延长病人生命的作用,甚至有可能带瘤生存。
本发明所述的中药组合物可用于治疗各种癌症,具有显著疗效。本发明治疗费用相对低廉,远远低于西医的治疗费用。
本发明还提供了一种由上述治疗该病的中药组合物制成的口服制剂,所述口服制剂包括口服液、片剂、胶囊剂、丸剂等,优选剂型为口服液和胶囊剂,一日一剂,分早晚两次服用。
本发明的中药组合物可以制备成多种剂型。例如,将煎煮后的药液杀菌消毒后装袋,制成口服液;或者将煎煮后的药液进行浓缩,烘干后,加入医学上可接收的辅料,然后制成片剂、胶囊剂、丸剂等。
所述医学上可接收的辅料包括淀粉、糊精、羧甲基纤维素钠、聚乙二醇、磷酸氢钙、海藻酸钠、山梨酸钾等。
以上所述,仅是本发明的较佳实施例而已,并非对本发明作任何形式上的限制,本领域技术人员利用上述揭示的技术内容做出些许简单修改、等同变化或修饰,均落在本发明的保护范围内。
Claims (4)
1.一种治疗癌症的中药,其特征是由下列重量份的原料药组成:皂角刺、啤酒花、漏芦5~10重量份;竹黄、款冬花、菟丝子6~12重量份;南蛇藤、贯叶金丝桃9~18重量份;七叶莲、绞股蓝、排钱树15~30重量份。
2.根据权利要求1所述的一种治疗癌症的中药,其特征是由下列重量份的原料药组成:皂角刺、啤酒花、漏芦10重量份;竹黄、款冬花、菟丝子12重量份;南蛇藤、贯叶金丝桃18重量份;七叶莲、绞股蓝、排钱树30重量份。
3.一种治疗癌症的口服制剂,其特征是由权利要求1或2中任一项所述的中药组合物制成。
4.根据权利要求3所述的一种治疗癌症的口服制剂,其特征是,所述口服制剂包括口服液、片剂、胶囊剂、丸剂,优选口服液和片剂。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010821456X | 2020-08-15 | ||
CN202010821456.XA CN112426466A (zh) | 2020-08-15 | 2020-08-15 | 一种治疗各种癌症的中药组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113209201A true CN113209201A (zh) | 2021-08-06 |
Family
ID=74690335
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010821456.XA Pending CN112426466A (zh) | 2020-08-15 | 2020-08-15 | 一种治疗各种癌症的中药组合物 |
CN202110715494.1A Pending CN113209201A (zh) | 2020-08-15 | 2021-06-28 | 一种治疗各种癌症的中药组合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010821456.XA Pending CN112426466A (zh) | 2020-08-15 | 2020-08-15 | 一种治疗各种癌症的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN112426466A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113368205A (zh) * | 2020-08-15 | 2021-09-10 | 仲崇允 | 一种治疗胃癌的中药组合物 |
-
2020
- 2020-08-15 CN CN202010821456.XA patent/CN112426466A/zh active Pending
-
2021
- 2021-06-28 CN CN202110715494.1A patent/CN113209201A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113368205A (zh) * | 2020-08-15 | 2021-09-10 | 仲崇允 | 一种治疗胃癌的中药组合物 |
Non-Patent Citations (1)
Title |
---|
徐辉德: "抗癌草药绞股蓝", 《农村实用技术与信息》, pages 1 - 2 * |
Also Published As
Publication number | Publication date |
---|---|
CN112426466A (zh) | 2021-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1935245A (zh) | 一种具有防癌、抗癌作用的营养粉 | |
US8715747B2 (en) | Biocomposition stimulant of the immune system, anti-tumor and anti-HIV | |
CN102688317A (zh) | 用于治疗肝癌的中药 | |
CN113304226A (zh) | 一种治疗肺癌的中药组合物 | |
CN113209201A (zh) | 一种治疗各种癌症的中药组合物 | |
WO2020042665A1 (zh) | 一种鲨鱼软骨糖蛋白及其抗癌用途 | |
CN113368205A (zh) | 一种治疗胃癌的中药组合物 | |
CN104434950B (zh) | 一种治疗结肠癌的杜仲靶向制剂及其制备方法 | |
CN106619870B (zh) | 治疗消化系统肿瘤的组合物及其制备方法 | |
CN112426491A (zh) | 一种治疗恶性黑色素瘤的中药组合物 | |
CN112426500A (zh) | 一种治疗宫颈癌的中药组合物 | |
CN104888128A (zh) | 一种治疗癌症的中药组合物 | |
CN112316071A (zh) | 一种治疗肝癌的中药组合物 | |
CN112426469A (zh) | 一种治疗艾氏腹水癌的中药组合物 | |
CN112426478A (zh) | 一种治疗肠癌的中药组合物 | |
CN104083643A (zh) | 治疗肿瘤和早、中期癌症的中药组合物及制备方法 | |
CN115154576B (zh) | 一种治疗恶性肿瘤相关性腹泻的中药组合物 | |
CN112426465A (zh) | 一种治疗鼻咽癌、鳞状细胞癌的中药组合物 | |
CN113648391A (zh) | 一种治疗白血病的中药组合物 | |
CN112426475A (zh) | 一种治疗淋巴细胞白血病的中药组合物 | |
CN102526630B (zh) | 治疗食道癌的中药、制备方法及给药方式 | |
CN112426486A (zh) | 一种治疗早幼粒细胞白血病的中药组合物 | |
CN112245518A (zh) | 一种治疗粒细胞型白血病的中药组合物 | |
CN111700951A (zh) | 一种治疗症瘕的中药组合物 | |
CN105213597A (zh) | 一种治疗肝癌、胃癌、肠癌的瑶药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210806 |
|
RJ01 | Rejection of invention patent application after publication |